TET2 and aplastic anemia: Thus, while Epag inhibits TET2 in TET dioxygenase–proficient bone marrow cells from patients with aplastic anemia, leading to HSPC expansion, in TET2-deficient leukemia cells it may restrict their growth because of their dependence on TET3 for demethylation of promoters and enhancers of survival and proliferative genes.